1 / 30

Developed by a Panel Convened by the International Association of Providers of AIDS Care

GUIDELINES FOR IMPROVING ENTRY INTO AND RETENTION IN CARE AND ANTIRETROVIRAL ADHERENCE FOR PERSONS WITH HIV. Developed by a Panel Convened by the International Association of Providers of AIDS Care. ABOUT THIS PRESENTATION.

maleah
Download Presentation

Developed by a Panel Convened by the International Association of Providers of AIDS Care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GUIDELINES FOR IMPROVING ENTRY INTO AND RETENTION IN CARE AND ANTIRETROVIRAL ADHERENCE FOR PERSONS WITH HIV Developed by a Panel Convened by the International Association of Providers of AIDS Care

  2. ABOUT THIS PRESENTATION • This presentation is based on guidelines e-published March 5, 2012, by the Annals of Internal Medicine.* • The target audience includes healthcare providers, patients, policymakers, and organizations and health systems involved with delivering HIV care, treatment, and support services. • These slides should be used as prepared, without changes in content or attribution. * Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for Improving Entry into and Retention in Care and Antiretroviral Adherence for Persons with HIV: Evidence-Based Recommendations from an International Association of Physicians in AIDS Care Panel. Ann Intern Med. 2012; e-published March 5, 2012.

  3. GUIDELINES OUTLINE • Background and methodology • Grading scales for the quality of evidence and strength of recommendations • Recommendations/practical applications for: • Entry into and retention in HIV care • ART adherence • Special populations

  4. BACKGROUND • The availability of potent antiretroviral therapy (ART) has resulted in remarkable decreases in HIV-related morbidity and mortality. • Timely entry into and retention in HIV care are essential to the provision of effective ART. • Of persons who know their HIV status in the United States, only 69% were linked to care and only 59% were retained in care. • High-level ART adherence is among the key determinants of successful HIV treatment outcome and is essential to minimize the emergence of drug resistance.

  5. BACKGROUND (continued) • CDC data reveals that only 28% of persons with HIV in the United States have achieved viral suppression – which speaks to suboptimal ART adherence, among other factors. • To date, there has not been a full evaluation of the evidence base for how to best monitor or support engagement in HIV care and ART adherence. • These guidelines are evidence-based recommendations to help providers optimize entry into and retention in care and support ART adherence for people living with HIV.

  6. METHODS • A systematic literature search was conducted to produce an evidence base restricted to randomized controlled trials (RCTs) and observational studies with comparators that had at least 1 measured biological or behavioral endpoint. • A total of 325 studies met the criteria. • Panel members drafted recommendations based on the body of evidence for each method or intervention and then graded the overall quality of the body of evidence and strength for each recommendation.

  7. GRADING SCALE: QUALITY OF EVIDENCE

  8. GRADING SCALE: STRENGTH OF RECOMMENDATION

  9. WHAT THESE GUIDELINES ADDRESS • Entry and retention in HIV care • Monitoring ART adherence • Interventions to improve ART Adherence • Adherence tools for patients • Education and counseling interventions • Health system and service delivery interventions • Special populations

  10. ENTRY INTO AND RETENTION IN CARE • Associations between entry into and retention in HIV medical care and both individual health outcomes and HIV transmission have been well established in retrospective, prospective and mathematical modeling studies. • Individual-level monitoring of entry and retention in care is essential to developing and evaluating interventions.

  11. RECOMMENDATIONS:ENTRY INTO/RETENTION IN CARE • Systematic monitoring of successful entry into HIV care is recommended for all individuals diagnosed with HIV (II A). • Systematic monitoring of retention in HIV care is recommended for all patients (II A). • Brief, strengths-based case management for individuals with a new HIV diagnosis is recommended (II B). • Intensive outreach for individuals not engaged in medical care within 6 months of a new HIV diagnosis may be considered (III C). • Use of peer or paraprofessional patient navigators may be considered (III C).

  12. PRACTICAL APPLICATIONS*:ENTRY INTO/RETENTION IN CARE • Integration of multiple data sources, including surveillance data, administrative databases, and medical clinic records, may enhance monitoring of initial entry into and retention in HIV care. • Many retention measures (for example, gaps in care, and visits per interval of time) and data sources (for example, surveillance, medical records, and administrative databases) have been used. *Practical applications of A-level recommendations

  13. RECOMMENDATIONS:MONITORING ART ADHERENCE • Self-reported adherence should be obtained routinely in all patients (II A). • Pharmacy refill data are recommended for adherence monitoring when medication refills are not automatically sent to patients (II B). • Drug concentrations in biological samples are not routinely recommended (III C). • Pill counts performed by staff or patients are not routinely recommended (III C). • Electronic drug monitors (EDMs) are not routinely recommended for clinical use (I C).

  14. PRACTICAL APPLICATIONS*:MONITORING ART ADHERENCE • Self-reported adherence is less strongly associated with treatment responses than are EDM- or pharmacy-based measures, but relative ease of implementation supports its use in clinical care. • Careful attention must be paid to collecting self-report data in a manner that makes reasonable demands on memory. • Questionnaires should inquire only about specific doses taken over a short time interval (e.g., in the previous week) and about global measures of adherence over a longer time interval (e.g. in the previous month). *Practical applications of A-level recommendations

  15. RECOMMENDATIONS:ART STRATEGIES • Among regimens of similar efficacy and tolerability, once-daily (QD) regimens are recommended for treatment-naive patients beginning ART (II B). • Switching treatment-experienced patients receiving complex or poorly tolerated regimens to once-daily (QD) regimens is recommended, given regimens with equivalent efficacy (III B). • Among regimens of equal efficacy and safety, fixed-dose combinations are recommended to decrease pill burden (III B).

  16. RECOMMENDATIONS:ADHERENCE TOOLS FOR PATIENTS • Reminder devices and use of communication technologies with an interactive component are recommended (I B). • Education and counselling using specific adherence-related tools is recommended (I A).

  17. PRACTICAL APPLICATIONS*:ADHERENCE TOOLS FOR PATIENTS • Adherence tools may be more beneficial when combined with education or counseling. • Studies have evaluated pillboxes, dose planners, reminder alarm device, and EDMs and most found positive effects on adherence. *Practical applications of A-level recommendations

  18. RECOMMENDATIONS:EDUCATION/COUNSELING • Individual one-on-one ART education is recommended (II A). • Providing one-on-one adherence support to patients through 1 or more adherence counselling approaches is recommended (II A). • Group education and group counselling are recommended; however, the type of group format, content, and implementation cannot be specified on the basis of the currently available evidence (II C). • Multidisciplinary education and counselling intervention approaches are recommended (III B). • Offering peer support may be considered (III C).

  19. PRACTICAL APPLICATIONS*:EDUCATION/COUNSELING • The majority of interventions with ART education had favorable effects on adherence. Most effective interventions included education along with counseling and skills-building along with activities to promote adult learning. • Evidence suggests the utility of providing discussion-based support and provides a wide array of potentially effective interventions that should be carefully matched to clinic population needs and resources. *Practical applications of A-level recommendations

  20. RECOMMENDATIONS:HEALTH SYSTEM/SERVICE DELIVERY • Using nurse- or community counsellor-based care has adherence and biological outcomes similar to those of doctor- or clinic counsellor-based care and is recommended in under-resourced settings (II B). • Interventions providing case management services and resources to address food insecurity, housing, and transportation needs are recommended (III B). • Integration of medication management services into pharmacy systems may be considered (III C). • Directly administered ART is not recommended for routine clinical care settings (I A).

  21. SPECIAL POPULATIONS • Treatment of a stigmatized and complex medical disorder with associated poor health outcomes is challenging in the best of circumstances. • The additional challenges of incarceration, poverty, food and housing instability, and substance use and mental health disorders can further complicate adherence and requires specialized interventions.

  22. RECOMMENDATIONS: PREGNANT WOMEN • Targeted PMTCT treatment (including HIV testing and serostatus awareness) improves adherence to ART for PMTCT and is recommended compared with an untargeted approach (treatment without HIV testing) in high HIV prevalence settings (III B). • Labor ward-based PMTCT adherence services are recommended for women who are not receiving ART before labor (II B).

  23. RECOMMENDATIONS: SUBSTANCE USE DISORDERS • Offering buprenorphine or methadone to opioid-dependent patients is recommended (II A). • DAART is recommended for individuals with substance use disorders (I B). • Integration of DAART into methadone maintenance treatment for opioid-dependent patients is recommended (II B).

  24. RECOMMENDATION: MENTAL HEALTH • Screening, management, and treatment for depression and other mental illnesses in combination with adherence counselling are recommended (II A).

  25. RECOMMENDATION: INCARCERATION • Directly administered ART (DAART) is recommended during incarceration (III B) and may be considered upon release to the community (II C).

  26. RECOMMENDATIONS:HOMELESS/MARGINALLY HOUSED INDIVIDUALS • Case management is recommended to mitigate multiple adherence barriers in the homeless (III B). • Pillbox organizers are recommended for persons who are homeless (II A).

  27. RECOMMENDATIONS: CHILDREN/ADOLESCENTS • Intensive youth-focused case management is recommended for adolescents and young adults living with HIV to improve entry into and retention in care (IV B). • Pediatric- and adolescent-focused therapeutic support interventions using problem-solving approaches and addressing psychosocial context are recommended (III B). • Pill-swallowing training is recommended and may be particularly helpful for younger patients (IV B). • DAART improves short-term treatment outcomes and may be considered in pediatric and adolescent patients (IV C).

  28. PRACTICAL APPLICATIONS*:SPECIAL POPULATIONS • Among patients with opioid dependence, both methadone and buprenorphine maintenance treatments improve medication adherence. • Combined mental health and ART adherence counseling interventions have significant impact on depressive symptoms, adherence and treatment outcomes. • Pillbox organizers offer a simple reminder of missed doses and are recommended for homeless persons. *Practical applications of A-level recommendations

  29. MISCELLANEOUS • To see the full text of the guidelines, visit: • http://www.annals.org/content/early/2012/03/05/0003-4819-156-11-201206050-00419?aimhp; or • www.iapac.org for a direct link to the full text, as well as a table summarizing the guidelines recommendations. • Visit the AETC NRC website for the most current version of this presentation: http://www.aidsetc.org • Visit www.iapac.orgto stay up-to-date on guidelines updates and guidelines-related activities, including CME opportunities. • This presentation was developed by Benjamin Young, MD, PhD, IAPAC Vice President/Chief Medical Officer.

More Related